Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

Participants needed: 70
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Acepodia Biotech, Inc.Updated: Oct 6, 2026Locations: 2
Eligibility criteria

Males or females aged 18 to 75 years [+12]

Other types of hepatic malignancies, such as mixed cholangiocarcinoma/HCC, sarco... [+14]

Read more
Status: Recruiting

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)

Participants needed: 34
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Acepodia Biotech, Inc.Updated: Oct 2, 2026Locations: 11
Eligibility criteria

Signed Informed Consent [+7]

Significant conditions that impair ability to receive study treatment or comply. [+11]

Read more
Status: Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Acepodia Biotech, Inc.Updated: Jul 1, 2025Locations: 9
Eligibility criteria

Locally advanced unresectable or metastatic solid tumors that have failed at lea... [+4]

Prior treatment with a genetically modified cell therapy product targeting EGFR [+9]

Read more